Iron supplementation in female blood donors deferred by copper sulfate screening.
Female blood donors with low hematocrit levels detected by copper sulfate screening were selected randomly to receive either 75 mg of iron per day, as ferrous gluconate, or a calcium phosphate placebo. Their ferritin, serum iron, total iron-binding capacity, zinc protoporphyrin, and hemoglobin values, as well as their suitability to donate blood, were determined initially (Visit 1) and at four follow-up visits (Visits 2-5). By the second visit, the serum ferritin and iron values of donors receiving iron supplementation differed significantly from those of donors receiving placebo. By the fifth visit, a less marked but significant increase in hemoglobin had occurred in the iron group, but not in the placebo group. At no time was there a significant difference between the groups' suitability to donate blood, with each group donating at almost half of their visits. The authors conclude that iron supplementation at this dose level in deferred female blood donors improves their iron status and hemoglobin levels, but does not significantly increase their suitability to donate blood as compared with the suitability of placebo-treated donors.
D000284:Administration, Oral; D001782:Blood Donors; D002986:Clinical Trials as Topic; D003300:Copper; D019327:Copper Sulfate; D005260:Female; D005293:Ferritins / Q000008:administration & dosage*; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D010919:Placebos; D012016:Reference Values; D014168:Transferrin / Q000032:analysis
D006454:Hemoglobins; D010919:Placebos; D014168:Transferrin; D003300:Copper; D005293:Ferritins; D019327:Copper Sulfate